Outlook Therapeutics, Inc.OTLKNASDAQ
LOADING
|||
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -145.17% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -145.38% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -128.80% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +81.23% | +42.54% | +86.23% | +116.36% | +58.77% |
| Weighted Average Shares Diluted Growth | +98.35% | +42.54% | +86.23% | +116.36% | +45.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +5.95% | -10.77% | -21.58% | -67.68% | -52.45% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -5.80% | -16.36% | -15.09% | -25.54% | +6.03% |
| R&D Expense Growth | +0.90% | +153.30% | +113.29% | -67.38% | -36.31% |
| SG&A Expenses Growth | +18.76% | +37.78% | +106.20% | +47.02% | +15.77% |